Malaysia Flash Note

DBS Group Research . Equity

IHH Healthcare (IHH MK):

Mkt. Cap: US\$11,277m | 3m Avg. Daily Val: US\$5.0m MY: BUY Last Traded Price (29 Nov 2019): RM5.37 Price Target 12-mth (MY): RM6.40 (19% upside)

SG: BUY Last Traded Price (29 Nov 2019): S\$1.75 Price Target 12-mth (SG): S\$2.10 (21% upside)

Analyst

Rachel TAN +65 6682 3713; racheltanlr@dbs.com Andy SIM, CFA +65 6682 3718; andysim@dbs.com

Foreign patients' growth in key markets

- 9M19 core profits fell on higher interest expenses and forex /fair value losses; mitigated by better operational performance and contributions from new hospitals including Fortis
- 9M19 revenue and EBITDA (ex-MFRS16) grew on constant currency basis
- Key highlights include strong operational performance in Singapore and Malaysia, EBITDA margin growth, opening of Gleneagles Chengdu, Gleneagles HK's additional beds and reduction of non-TRY debt to below US\$200m by year-end
- Maintain BUY; TP of RM6.40

Forecasts and Valuation

Forecasts and valuation				
FY Dec (RMm)	2018A	2019F	2020F	2021F
Revenue	11,521	15,124	16,201	17,329
EBITDA	2,492	3,097	3,407	3,741
Pre-tax Profit	752	1,073	1,645	1,916
Net Profit	628	701	1,020	1,162
Net Pft (Pre Ex.)	628	701	1,020	1,162
Net Pft Gth (Pre-ex) (%)	51.1	11.7	45.4	13.9
EPS (sen)	7.57	8.46	12.3	14.0
EPS Pre Ex. (sen)	7.57	8.46	12.3	14.0
EPS Gth Pre Ex (%)	50	12	45	14
Diluted EPS (sen)	6.53	7.42	11.3	13.0
Net DPS (sen)	3.00	2.22	2.95	2.65
BV Per Share (sen)	265	271	279	289
PE (X)	70.9	63.5	43.7	38.3
PE Pre Ex. (X)	70.9	63.5	43.7	38.3
P/Cash Flow (X)	24.0	18.2	18.2	17.0
EV/EBITDA (X)	21.6	17.0	15.0	13.3
Net Div Yield (%)	0.6	0.4	0.5	0.5
P/Book Value (X)	2.0	2.0	1.9	1.9
Net Debt/Equity (X)	0.1	0.1	0.0	CASH
ROAE (%)	2.9	3.2	4.5	4.9

Source of all data on this page: Company, DBS Bank, Bloomberg Finance L.P.



Refer to important disclosures at the end of this report

2 Dec 2019

Company Guide

Summary of our point of view, and highlights the relevant data points, which <u>IHH HeäthCigely</u> trading Login IHH Healthcare - Institution Login

What's New

9M19 core results impacted by higher interest expense:

IHH Healthcare (IHH) recorded 9M19 headline net profit of RM511m (vs RM118m in 9M18), in line with our FY19 estimates. The higher net profit was largely due to: i) lower foreign exchange (forex) translation losses from the Turkish Lira (TRY) which stabilised from a sharp depreciation in 3Q18 and ii) forex translation gains following the successful restructuring of non-TRY debt to only c.US\$250m, offset by higher interest expenses (estimated to have more than doubled) from higher borrowings to acquire Fortis Healthcare Ltd.

Excluding exceptional items, core profits fell -8% y-o-y to RM631m mainly due to higher net interest expenses and forex and fair value exchange losses on forward exchange contracts compared to gains recognised in 3Q18. However, this was partially mitigated by: i) better core operations performance from all key markets, ii) contributions from newly acquired hospitals including Amanjaya Specialist Centre Sdn Bhd and Fortis Healthcare (total earnings before interest, tax, depreciation and amortisation (EBITDA) of RM292mn) and iii) one-off items including reversal of RM21.8m accrued interest on prior years' tax payable and RM28.5m of trustee management fee income from disposal of Singapore-listed Religare Health Trust's (RHT) assets.

9M19 revenue jumped +33% y-o-y to RM11.1b mainly from contributions from Fortis. Excluding Fortis, revenue increased +8% y-o-y from all key markets; Singapore (+11% y-o-y), Malaysia (+17% y-o-y), North Asia (+27% y-o-y largely from Gleneagles Hong Kong (HK) Hospital) and Turkey (+1% y-oy). On constant currency basis, 9M19 revenue improved +38% y-o-y.

9M19 EBITDA grew +38% y-o-y to RM2.4bn, in line with both ours and consensus' estimates. This was mainly from good underlying operational performance, contributions from Fortis and impact from Malaysian Financial Reporting Standards 16 (MFRS16) adjustments. The EBITDA growth was largely from Singapore (+28% y-o-y), Malaysia (+23% y-o-y), Turkey (+39% y-o-y) and lower losses from Gleneagles HK (-23% y-o-y), partially offset by start-up losses from Gleneagles Chengdu estimated at c.RM25m. On constant currency basis and ex-MFRS16 impact, EBITDA grew +27% y-o-y.

3Q19 recorded headline net profit of RM236m (vs RM104m net loss in 3Q18) mainly from lower forex translation losses offset by higher interest expense. Core profits fell 35% y-o-y on higher financing costs, as well as forex and fair value forex losses. 3Q19 revenue and EBITDA rose +33% y-o-y and 34% y-o-y respectively and on constant currency (ex-MFRS 16) revenue and EBITDA grew +36% y-o-y and 22% y-o-y respectively.

EBITDA margins (ex- Parkway Life REIT (PLife REIT)) improved by 2.1p.p q-o-q to 21.6% from 19.5% in 2Q19. Similarly, EBITDA margins (ex-new hospitals; ex- PLife REIT) improved q-o-q to 25.1% from 23% in 2Q19. The improved EBITDA margins were mainly led by Singapore and Malaysia partially due to higher foreign patients.

Key operational highlights:

- Gleneagles HK occupancy dipped marginally to 58% from above 60% previously but average revenue per inpatient admissions (ARPIA) grew +10% with 30 new beds in 4Q19.
- Strong underlying performance from all key markets partially led by growth in foreign patients.

- Management is targeting to lower non-TRY debt further to below US\$200 from current US\$250 by yearend.
- Fortis' EBITDA grew +42% q-o-q; India (ex-Fortis) turned EBITDA profitable after 3 consecutive quarters of losses.
- Gleneagles Chengdu Hospital opened in October 2019 with 100 operational beds, 24 doctors and ~200 employees

Gleneagles HK's EBITDA losses increased marginally q-o-q; occupancy fell to 58% but ARPIA grew+10% with 30 additional beds post 3Q19. Gleneagles HK's EBITDA losses increased marginally q-o-q to RM39.4m (vs RM34.5m in 2Q19; RM49.4m in 3Q18) partly impacted by deferrals of non-urgent and non-essential procedures and services following the HK protests and demonstrations. Occupancy fell marginally to 58% on 150 operational beds (vs above 60% previously, 62% in 2Q19 and 68% in 1Q19), However, there were encouraging signs with slightly higher ARPIA of HKD33k vs c.HKD30k previously. As guided previously, IHH increased 30 additional beds post 3Q19 to 180 operating beds.

Singapore - strong performance driven by foreign patients'

growth. In 3Q19 and 9M19, revenue from IHH's Singapore operations grew 11% y-o-y. Both 3Q19 ARPIA and inpatient volumes continued to grow moderately at 3.5% y-o-y and 4.4% y-o-y respectively. On a constant currency basis, revenue and EBITDA grew 10% y-o-y and 18% y-o-y respectively while EBITDA margins improved by 2.3p.p. y-o-y from better operating leverage and growth in foreign patients. IHH's management continues to see growth in foreign patients, with revenue comprising 25% of 3Q19 Singapore revenue (vs 26% in 2Q19 and 23% in FY18). The increase in foreign patients was mainly from Indonesia, Vietnam and China.

Malaysia – continued growth in Indonesian and Chinese patients. 3Q19 and 9M19 revenue from its Malaysia operations grew 20% and 17% y-o-y, led by: i) higher inpatient volumes (+14.9% y-o-y) and ARPIA (+4.3% y-o-y), ii) growth in foreign patients largely from Indonesia (especially in Penang) and China. Revenue contributions from foreign patients doubled to 6% from 3%-4%



previously. EBITDA margins remained stable at 29.3% in 3Q19 (vs 29.8% in 3Q18).

Acibadem – strong performance led by price adjustments and foreign patients; targeting to reduce non-TRY debt to below US\$200m by year-end. On a constant currency basis, Turkey based Acibadem Holdings' 3Q19 and 9M19 revenue grew 11% y-o-y and 19% y-o-y respectively while EBITDA grew 51% y-o-y and 65% respectively. The strong growth was partially led by strong growth in ARPIA of 12.3% y-o-y in 3Q19 despite inpatient volumes falling 6% (mainly due to lower local patients under the social scheme). The good results were led by price adjustments done earlier in the year (price increase imposed on private insurance and out-ofpocket patients to compensate for inflation), more complex cases and growth in foreign patients (comprises 15% of Acibadem's revenue).

Post restructuring / refinancing, IHH's management has successfully reduced its non-TRY debt to US\$250m as at June 2019, ahead of its FY2020 target. It is targeting to reduce this further to below US\$200m by year-end. This will substantially reduce exposure to forex translation volatility as seen in the positive results in 3Q19.

India – Fortis' EBITDA up +42% q-o-q; existing India hospitals turned EBITDA positive after 3 consecutive quarters of losses. 3Q19 and 9M19 revenue recorded RM876m and RM2.5b (vs RM162m and RM494m in 3Q18 and 9M18 respectively) on maiden contributions from Fortis. Fortis' operations continued to improve as it achieved its cost savings targets. Fortis' EBITDA grew 42% q-o-q following the improvement in its India operations. India (ex-Fortis) has turned EBITDA positive after 3 quarters of consecutive losses as it converts to a more multi-disciplinary focused hospital to reduce concentration risks on a single doctor.

In Fortis Healthcare's results briefing, management has achieved INR32 Crores in 1HFYE March 2020 vs 80 to 100 Crores (~RM60mn; c.19% of Fortis' annualized 1H19 EBITDA) cost savings in FYE March 20, mainly from rationalising manpower cost, other expenses and lower bad debt provisions. EBITDA margins have improved from 12.5% to 15.7%. If successful, contribution from Fortis Healthcare could grow at a faster pace in the medium-term. The Supreme Court has issued a suo moto notice of contempt to Fortis Healthcare. The next court hearing is on 3 February 2020. Please refer to our previous report for further details - *IHH Healthcare: Back in Limbo*.

China – Gleneagles Chengdu opened in October 2019 with 100 operational beds. Gleneagles Chengdu opened in October 2019 with 100 operational beds, 200 employees of which 24 doctors were hired. Its management has signed on with a few insurance companies (eg ING, SOS) and expects to ramp-up with signups with more insurance companies and key specialisation (pediatrics, cardiology and gastro).

Maintain BUY, raised TP to RM6.40. We maintain our BUY rating and target price (TP) of RM6.40. IHH currently trades at 15x FY20F enterprise value/EBITDA (EV/EBITDA), below 1SD (standard deviation) of its historical average. We remain positive on IHH's long-term growth plans, with a pipeline of new hospitals in China and a potential escalation of expansion into India. We believe the ramp-up in Gleneagles HK and better economic prospects in home countries such as Malaysia and Singapore could offset some of the start-up losses in China and lead IHH onto its next phase of growth.

IHH's medium-term outlook is bright while it rides out its near-term headwinds and gestation period for the new hospitals. In addition, with a potentially strong platform in India and another in China, IHH now has exposure to the two largest economies in Asia with the highest growth potential in the healthcare sector. We believe this further elevates IHH's long-term potential.

The key catalysts are: i) Gleneagles HK to turn EBITDA positive and shorter-than-expected gestation period from other new hospitals, ii) better-than-expected organic performance, iii) turnaround in the situation in Turkey, iii) positive developments in new markets such as India.




Quarterly / Interim Income Statement (RMm)

3Q2018	2Q2019	3Q2019	% chg yoy	% chg qoq
2,841	3,645	3,788	33.4	3.9
(2,408)	(3,193)	(3,292)	36.7	3.1
433	453	496	14.6	9.6
0.0	0.0	0.0	-	-
1.03	4.00	4.13	300.6	3.5
(751)	(191)	(106)	85.8	44.4
0.0	0.0	0.0	-	-
(317)	266	394	nm	48.4
250	(63.7)	(112)	(144.9)	76.4
(37.8)	(16.9)	(45.5)	(20.5)	168.9
(104)	185	236	nm	27.8
(104)	185	236	nm	27.8
664	791	836	25.9	5.6
15.2	12.4	13.1		
(3.7)	5.1	6.2		
	2,841 (2,408) 433 0.0 1.03 (751) 0.0 (317) 250 (37.8) (104) (104) 664 15.2	2,841 3,645 (2,408) (3,193) 433 453 0.0 0.0 1.03 4.00 (751) (191) 0.0 0.0 (317) 266 250 (63.7) (37.8) (16.9) (104) 185 664 791 15.2 12.4	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2,841 $3,645$ $3,788$ 33.4 $(2,408)$ $(3,193)$ $(3,292)$ 36.7 43345349614.6 0.0 0.0 0.0 $ 1.03$ 4.00 4.13 300.6 (751) (191) (106) 85.8 0.0 0.0 0.0 $-$ (317)266394nm 250 (63.7) (112) (144.9) (37.8) (16.9) (45.5) (20.5) (104)185236nm 664 791 836 25.9 15.2 12.4 13.1

Source of all data: Company, DBS Bank

Target Price & Ratings History



Note : Sha	re nrice and	Target r	nrice are a	diustad	for cor	norate	actions
NOLE . JIIA	ie price ariu	raryerp	nice are a	ujusteu	101 201	pulate	actions.

Source: DBS Bank Analyst: Rachel TAN Andy SIM, CFA

S.No.	Date of Report	Closing Price	12-mth Target Price	Rating
1:	02 Sep 19	5.79	6.40	BUY
2:	18 Sep 19	5.75	6.40	BUY
3:	19 Nov 19	5.45	6.40	BUY



DBS Bank recommendations are based on an Absolute Total Return* Rating system, defined as follows: STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame) BUY (>15% total return over the next 12 months for small caps, >10% for large caps) HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps) FULLY VALUED (negative total return, i.e., > -10% over the next 12 months) SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 2 Dec 2019 08:43:40 (SGT) Dissemination Date: 2 Dec 2019 08:58:29 (SGT)

Sources for all charts and tables are DBS Bank unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd. This report is solely intended for the clients of DBS Bank Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "**DBS Group**") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.



Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

- 1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd (''DBSVS'') or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 31 Oct 2019
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd (''DBSVS''), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd (''DBSVS''), their subsidiaries and/or other affiliates in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.
	DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.
	Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.
Hong Kong	This report has been prepared by a person(s) who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited, a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures (Chapter 571 of the Laws of Hong Kong).
	For any query regarding the materials herein, please contact Carol Wu (Reg No. AH8283) at dbsvhk@dbs.com
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.
	And
	Wong Ming Tek, Executive Director, ADBSR
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.



Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore. This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
	In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608 - 610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

DBS Regional Research Offices

HONG KONG

DBS (Hong Kong) Ltd Contact: Carol Wu 13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: 852 3668 4181 Fax: 852 2521 1812 e-mail: dbsvhk@dbs.com

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269 e-mail: research@th.dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission, Thailand

MALAYSIA

AllianceDBS Research Sdn Bhd

Contact: Wong Ming Tek (128540 U) 19th Floor, Menara Multi-Purpose, Capital Square, 8 Jalan Munshi Abdullah 50100 Kuala Lumpur, Malaysia. Tel.: 603 2604 3333 Fax: 603 2604 3921 e-mail: general@alliancedbs.com

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943 e-mail: indonesiaresearch@dbs.com

SINGAPORE

DBS Bank Ltd Contact: Janice Chua 12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982 Tel: 65 6878 8888 Fax: 65 65353 418 e-mail: equityresearch@dbs.com Company Regn. No. 196800306E

